The Michael J. Fox Foundation for Parkinson's Research

This election season, California voters are considering Proposition 38, a ballot measure that would authorize $8.4 billion in state bonds for immunology and immunotherapy research at California institutions. While the measure is not solely focused on Parkinson’s research, it could help advance breakthroughs that benefit the community as researchers learn more about the immune system’s role in Parkinson’s. The Michael J.

About Juvmo (tavapadon) In September 2026, the U.S. Food and Drug Administration (FDA) approved Juvmo (tavapadon), a once-daily oral medication for the treatment of motor symptoms of Parkinson’s disease. It was studied both as a standalone treatment in early Parkinson’s and as an add-on to levodopa in people with progressing Parkinson’s. Tavapadon is a dopamine agonist — a class of Parkinson’s drugs that mimics dopamine, the brain chemical that becomes depleted in Parkinson’s.

Every morning, Rochelle starts her day with a nudge from her cat, Cosmo, a cup of coffee and time reading scripture. Then comes the daily Jumble puzzle, which has become a friendly competition with her son. Rochelle tries to solve it before he gets a look — and says she usually wins. At 98 years old, Rochelle enjoys staying mentally sharp and credits her family with helping her stay active and connected.

The U.S. Food and Drug Administration (FDA) has approved tavapadon, a once-daily oral medication for the treatment of motor symptoms of Parkinson’s disease. Tavapadon, which will be sold under the brand name Juvmo, is a new drug in an existing class of Parkinson’s drugs: dopamine agonists. These medications act like dopamine, the brain chemical that decreases in Parkinson’s and causes movement symptoms such as slowness, stiffness and tremor.

Anne Smith on the Atlantic City boardwalk in New Jersey to honor her father’s legacy. Photos courtesy of Anne Smith. Ten years after losing her father to Parkinson’s, Run/Walk Series fundraiser Anne Smith, of Palmyra, New Jersey, turned a difficult anniversary into a day-long tribute to his life — and a call to support the research he cared about. On August 19, Anne traveled 63 miles to Atlantic City, New Jersey, near where her father was born.

NEW YORK (September 17, 2026) — As part of its unwavering commitment to accelerate Parkinson’s research, The Michael J. Fox Foundation for Parkinson’s Research (MJFF) today announces All Grit. No Quit. — an ambitious multi-year $2.5-billion fundraising campaign to accelerate the development of next-generation treatment breakthroughs and a cure for Parkinson’s disease. Marking a critical inflection point for the field, All Grit. No Quit. is the Foundation’s first multi-year fundraising campaign.

Another remarkable honor for our intrepid founder! Michael J. Fox received the Television Academy’s Bob Hope Humanitarian Award in recognition of his transformative contributions to Parkinson’s disease research and advocacy. Michael was presented with the honor at the 78th Emmy Awards on September 14, 2026, becoming only the sixth person to be recognized with the award.

In 2021, six teams took their swings for something bigger than a spot on the leaderboard: a future without Parkinson’s disease (PD). That first Targeting a Cure fundraiser has since grown into a nationwide Topgolf event where supporters of all ages and abilities gather in cities across the country for friendly competition and a shared mission to fund PD research.

Team Fox Young Professionals, also referred to as YPs, serve as long-term ambassadors for The Michael J. Fox Foundation by hosting fundraisers, attending events and connecting with the community at a local level. While many YPs have a personal connection to Parkinson’s disease, many are simply inspired to join our movement to speed a cure. 100% of the Young Professional’s proceeds go directly to the Michael J. Fox Foundation’s programs to find a cure for Parkinson’s disease.

On September 9, 2026, Michael J. Fox received the 2026 Lasker~Bloomberg Public Service Award, one of the nation’s highest honors in biomedical science, recognizing his work to empower the voices of people with Parkinson’s and accelerate research toward better treatments and a cure. For Michael, the recognition belongs to a much larger community. “Receiving a Lasker is humbling,” Michael said.